FTC Seeks Contempt Ruling Against Martin Shkreli for Pharma Ban Violations
The Federal Trade Commission and seven state attorneys general ask a federal court to hold him in contempt for trading stocks and sharing advice.
First reported by Quartz, 1h 00m ahead of the next publisher · who breaks stories first
The story so far
7 publishers have covered this in 7 articles since 13 Oct 2026. Quartz published first, on 13 October at 13:30 UTC; STAT followed 1h 01m later. The most recent article, from The Hill, appeared on 13 October at 17:05 UTC.
Outlets reporting it: News Feed (major outlet), The Guardian US (major outlet), The Hill (major outlet), Quartz, STAT, MarketWatch, All Content from Business Insider.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- QuartzFTC and 7 states are seeking to hold Martin Shkreli in contempt over pharma ban
- STATSTAT+: FTC demands Martin Shkreli divest his pharma stocks
- MarketWatch‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
- All Content from Business InsiderFTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
- News FeedFTC says ‘pharma bro’ Martin Shkreli repeatedly violated industry ban
- The Guardian USFTC and seven states seek contempt ruling against Shkreli over pharma ban
- The HillFTC: 'Pharma bro' Shkreli violated lifetime industry ban, should be held in contempt
Sources
Every article we clustered into this story. Headlines link to the publisher.
- FTC: 'Pharma bro' Shkreli violated lifetime industry ban, should be held in contempt The Hill ·
- FTC and seven states seek contempt ruling against Shkreli over pharma ban The Guardian US ·
- FTC says ‘pharma bro’ Martin Shkreli repeatedly violated industry ban News Feed ·
- FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban All Content from Business Insider
- ‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks MarketWatch
- STAT+: FTC demands Martin Shkreli divest his pharma stocks STAT
- FTC and 7 states are seeking to hold Martin Shkreli in contempt over pharma ban Quartz
In this story
- Martin Shkreli
- FTC